VSV-based Therapeutic Papilloma Vaccine

基于 VSV 的治疗性乳头状瘤疫苗

• 批准号: 6761813
• 负责人: JANET L BRANDSMA
• 金额: $ 32.74万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-06-17 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6761813
• 关键词: Adenoviridae; Papillomavirus; Vesiculovirus; antigen antibody reaction; biotechnology; cancer prevention; cervix neoplasms; chimeric proteins; disease /disorder model; enzyme linked immunosorbent assay; human papillomavirus; immunization; immunoprecipitation; immunotherapy; laboratory rabbit; molecular cloning; nonhuman therapy evaluation; rabbit papillomavirus; remission /regression; sexually transmitted diseases; tumor antigens; ubiquitin; vaccine development; vector vaccine; virus envelope; western blottings

DESCRIPTION (provided by applicant): Human papillomavirus (HPV) infection of the cervix initiates the development of cervical cancer. Vaccination has the potential to prevent cervical cancer by preventing primary HPV infection and by eliminating persistent lesions. The ideal vaccine would induce therapeutic as well as protective immunity. The best animal model for therapeutic vaccine development is the cottontail rabbit papillomavirus (CRPV)-rabbit model. Live recombinant vesicular stomatitis viruses (rVSV) expressing foreign viral proteins have successfully protected animals against challenges with several human viruses. We recently generated an rVSV vector expressing the CRPV E6 tumor antigen and used it to vaccinate rabbits with well-established tumors (papillomas) in a preliminary experiment. The treatment induced dramatic therapeutic outcomes including the complete and permanent regression of all disease in some rabbits with a total papilloma burden of 4 cm3, as compared to no regression in the controls. The hypothesis of this application is that the rVSV-E6 vaccine can be improved to induce more rapid and more universal regression. It is based on the observation that the original vaccine expressed a relatively low level of E6 protein and that revaccination with the same rVSV-E6 was probably not effective, due to VSV-specific neutralizing antibodies induced by primary vaccination. The efficacy of the rVSV-E6 could also be improved by modifying the E6 gene to encode a ubiquitin-E6 fusion protein (UbE6), based on our findings, using CRPV DNA vaccines, that a UbE6 fused gene was markedly more effective than the unfused E6 gene. The specific aims are to repeat the preliminary experiment with larger group size and all appropriate controls; to determine if more rapid and more universal tumor clearance can be obtained using VSV vectors giving higher-level expression of E6 or expressing UbE6, using an efficient VSV-E6 boosting vector with the VSV envelope gene from a heterologous serotype, or using a completely heterologous viral vector (adenovirus). We will determine if the most effective therapeutic vaccine also induces protective immunity. The data provided by this investigation are likely to aid in the development a highly effective HPV vaccine to protect women against cervical cancer.

描述（由申请人提供）：子宫颈的人乳头瘤病毒（HPV）感染引发子宫颈癌的发展。疫苗接种有可能通过预防原发性 HPV 感染和消除持续性病变来预防宫颈癌。理想的疫苗应诱导治疗性免疫和保护性免疫。治疗性疫苗开发的最佳动物模型是棉尾兔乳头瘤病毒（CRPV）-兔模型。表达外源病毒蛋白的活重组水泡性口炎病毒（rVSV）已成功保护动物免受多种人类病毒的攻击。我们最近生成了表达 CRPV E6 肿瘤抗原的 rVSV 载体，并在初步实验中用它对患有已形成肿瘤（乳头状瘤）的兔子进行疫苗接种。该治疗产生了显着的治疗结果，包括一些乳头状瘤总负荷为 4 cm3 的兔子的所有疾病完全且永久消退，而对照组则没有消退。本申请的假设是，rVSV-E6疫苗可以经过改进以诱导更快速和更普遍的消退。这是基于以下观察：原始疫苗表达的E6蛋白水平相对较低，并且由于初次疫苗接种诱导的VSV特异性中和抗体，用相同的rVSV-E6重新疫苗接种可能无效。 rVSV-E6 的功效也可以通过修改 E6 基因编码泛素-E6 融合蛋白 (UbE6) 来提高，根据我们的研究结果，使用 CRPV DNA 疫苗，UbE6 融合基因明显比未融合的更有效E6基因。具体目标是用更大的组规模和所有适当的对照重复初步实验；以确定是否可以使用提供更高水平表达 E6 或表达 UbE6 的 VSV 载体、使用具有来自异源血清型的 VSV 包膜基因的高效 VSV-E6 加强载体或使用完全异源的 VSV-E6 加强载体来获得更快速和更普遍的肿瘤清除病毒载体（腺病毒）。我们将确定最有效的治疗性疫苗是否也能诱导保护性免疫。这项调查提供的数据可能有助于开发一种高效的 HPV 疫苗，以保护女性免受宫颈癌的侵害。